AGER-dependent macropinocytosis drives resistance to KRAS-G12D-targeted therapy in advanced pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) driven by the mutation presents a formidable health challenge because of limited treatment options. MRTX1133 is a highly selective and first-in-class KRAS-G12D inhibitor under clinical development. Here, we report that the advanced glycosylation end product-specific receptor (AGER) plays a key role in mediating MRTX1133 resistance in PDAC cells.

Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells.

Background: Cell therapy demonstrates promising potential as a substitute therapeutic approach for liver cirrhosis. We have developed a strategy to effectively expand murine and human hepatocyte-derived liver progenitor-like cells (HepLPCs) in vitro. The primary objective of the present study was to apply HepLPCs to the treatment of liver cirrhosis and to elucidate the underlying mechanisms responsible for their therapeutic efficacy.

Dual-energy CT-derived virtual noncalcium imaging to assess bone marrow lesions in patients with knee osteoarthritis.

To determine the diagnostic performance of dual-energy CT (DECT) virtual noncalcium (VNCa) technique in the detection of bone marrow lesions (BMLs) in knee osteoarthritis, and further analyze the correlation between the severity of BMLs on VNCa image and the degree of knee pain. 23 consecutive patients with clinically diagnosed knee osteoarthritis were underwent DECT and 3.0T MRI between August 2017 and November 2018.

Impact of anatomical features of non-thrombotic left iliac venous compression on the development of venous leg ulcers based on CT venography.

Purpose: To explore the anatomical features of left iliac vein (LIV) in non-thrombotic venous leg ulcers (VLUs) and to identify the impact of these anatomical features on VLUs based on computed tomography venography (CTV).

Methods: This is a retrospective, single-center study of a database (2021-2023) of 431 patients with non-thrombotic chronic venous insufficiency. According to CEAP clinical (C) classifications, cases of C6 and C2 were included for analysis as case and control groups.

IDO1 inhibits ferroptosis by regulating FTO-mediated m6A methylation and SLC7A11 mRNA stability during glioblastoma progression.

Indoleamine 2, 3-dioxygenase 1 (IDO1) has been recognized as an enzyme involved in tryptophan catabolism with immunosuppressive ability. This study determined to investigate the impact of IDO1 on glioblastoma multiforme (GBM) cells. Here, we showed that the expression of IDO1 was markedly increased in patients with glioma and associated with GBM progression.